Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients

Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict... Ann Hematol (2017) 96:1587–1588 DOI 10.1007/s00277-017-3052-4 LETTER TO THE EDITOR Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients 1,2 2 2 Hiroshi Ureshino & Kazuharu Kamachi & Masaharu Miyahara Received: 23 May 2017 /Accepted: 15 June 2017 /Published online: 27 June 2017 Springer-Verlag GmbH Germany 2017 Dear Editor, genase and soluble interleukin-2 receptor did not decrease, Human T-cell lymphotropic virus type I (HTLV-I) specific indicating that ATL was refractory. Subsequently, cytotoxic T lymphocytes (CTLs) exhibit cytotoxicity against mogamulizumab and half-doses of cyclophosphamide, doxo- HTLV-I infected T-cells, resulting in the regulation of HTLV-I rubicin, vincristine, and prednisolone (CHOP) were adminis- tered. After two courses of chemotherapy, the patient achieved proviral load. CTLs are rarely seen in adult T-cell leukemia/ lymphoma (ATL) patients, but are strongly activated in some and remained in CR >42 months. HTLV-I specific CTLs were ATL patients who remain in complete remission (CR) after detected (0.38%) in her PB at 14 months after allogenic stem cell transplantation (allo-SCT) [1]; moreover, mogamulizumab administration (Fig. 1). CTLs also regulate ATL disease progression [2]. Tax peptide- Our patient achieved extremely long-term remission after pulsed dendritic cell vaccination can strongly http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients

Loading next page...
 
/lp/springer_journal/detection-of-human-t-cell-lymphotropic-virus-type-i-specific-cytotoxic-cL5365pyij
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag GmbH Germany
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
D.O.I.
10.1007/s00277-017-3052-4
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial